The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback